CELGENE RPC 1063
This study is designed to provide data on the immune response and safety of administering vaccines to relapsing multiple sclerosis (RMS) participants taking ozanimod compared to controls taking interferon-beta's or receiving no disease modifying…
- Investigator
- Torge Rempe
- Status
- Accepting Candidates
- Ages
- 18 Years - 65 Years
- Sexes
- All
NARCRMS
- Investigator
- Torge Rempe
- Status
- Accepting Candidates
TREAT-MS
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early…
- Investigator
- Torge Rempe
- Status
- Accepting Candidates
- Ages
- 18 Years - 60 Years
- Sexes
- All